Merck Oncology Advancements Highlight Long-Term Data and Pipeline Progress at ASCO 2026

Merck oncology advancements continue to deliver meaningful progress for patients. New long-term data from multiple trials highlight sustained survival benefits across lung cancer, breast cancer, melanoma, and other tumor types.

These advancements will feature prominently at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where the company plans to share more than 100 abstracts covering over 25 tumor types, including five-year follow-up results.

What Are the Most Impactful Findings?

Key data demonstrate durable efficacy and expand treatment options across multiple disease settings. Notable highlights include:

• Five-year follow-up from the Phase 2b KEYNOTE-942 trial supports the ongoing potential of intismeran autogene combined with KEYTRUDA in resected high-risk melanoma.
• Final analysis of the Phase 3 KEYNOTE-522 study confirms a sustained survival benefit when KEYTRUDA is added to chemotherapy as neoadjuvant therapy and continued as adjuvant treatment for high-risk early-stage triple-negative breast cancer.
• New results from the Phase 3 OptiTROP-Lung05 trial evaluate sacituzumab tirumotecan plus KEYTRUDA in advanced non-small cell lung cancer.
• Progression-free survival data from the Phase 3 ASCENT-04/KEYNOTE-D19 study will be featured in the official ASCO 2026 Press Program. The study evaluates KEYTRUDA in combination with Trodelvy in previously untreated PD-L1-positive metastatic triple-negative breast cancer.

Additional abstracts include six-year median follow-up data in gastric cancer, extended follow-up in von Hippel-Lindau disease-associated neoplasms, and quality-of-life outcomes in urothelial carcinoma.

How Was the Research Conducted?

Merck’s presentations draw from rigorously designed clinical trials featuring extended follow-up periods. The KEYNOTE-942 study is a Phase 2b trial assessing individualized neoantigen therapy in the adjuvant melanoma setting. KEYNOTE-522 is a Phase 3 neoadjuvant-plus-adjuvant study, OptiTROP-Lung05 is a China-led Phase 3 randomized trial, and ASCENT-04/KEYNOTE-D19 evaluates the combination in patients with metastatic triple-negative breast cancer.

Intismeran autogene is an mRNA-based individualized neoantigen therapy that encodes up to 34 patient-specific neoantigens. Sacituzumab tirumotecan (Sac-TMT) is a TROP2-directed antibody-drug conjugate carrying a topoisomerase I inhibitor payload, while raludotatug deruxtecan is a CDH6-directed antibody-drug conjugate. These programs are advanced through strategic collaborations with Moderna, Kelun-Biotech, Gilead, Astellas/Pfizer, and Daiichi Sankyo.

What Implications Do These Results Hold?

The long-term survival signals suggest opportunities to refine value assessments in health economics and outcomes research. Extended follow-up data from trials such as KEYNOTE-942 and KEYNOTE-522 may support more favorable cost-effectiveness models by better quantifying the durable benefits observed in high-risk early-stage and resected disease settings.

Merck’s oncology portfolio at ASCO 2026 also features health-related quality-of-life analyses from studies such as KEYNOTE-905 and the AMBASSADOR trial. The broader pipeline includes 17 ongoing Phase 3 trials for sac-TMT. Explore these developments in this detailed analysis.

FAQ

How does the five-year KEYNOTE-942 update affect expectations for individualized neoantigen therapy?

The data underscore the continued potential of intismeran autogene combined with KEYTRUDA in resected high-risk melanoma and support further evaluation of this personalized approach.

What survival benefit does the final KEYNOTE-522 analysis demonstrate?

Results show sustained overall survival improvement with KEYTRUDA plus chemotherapy in both the neoadjuvant and adjuvant settings for high-risk early-stage triple-negative breast cancer.

Where can I find more details on Merck’s full ASCO 2026 presentations?

Merck will host an Oncology Investor Event on June 1, 2026. Additional abstracts cover gastrointestinal, genitourinary, gynecologic, and lung cancers, along with biomarker research.